Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05824403
Recruiting Observational

PAncreatic Disease Cohort of TOuLouse

NCT05824403 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Toulouse
Phase
Observational
Started
2023-11-28
Last updated
2023-12-04

Condition(s) studied

Pancreatic Diseases

Study summary

This study is a prospective cohort dedicated to pancreatic diseases excluding cancer. The aim is to develop positive or differential diagnostic tools between benign potentially malignant or malignant pancreatic pathologies. During this study the investigators collect data and biological samples to support research project.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with inflammatory or cystic exocrine pancreatic pathology * Patient able to read and understand the information leaflet * Patients who have agreed to participate in the study and have signed the free and informed consent * Patients affiliated to a social security system (including AME) Exclusion Criteria: * Patient with pancreatic cancer pathology * Patients with active cancer, whatever the origin * Pregnant or breastfeeding patients * Patients under legal protection, guardianship or trusteeship

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Rangueil hospital Toulouse France Recruiting

More University Hospital, Toulouse trials in France

Adapted Physical Activity for Children Treated With Cancer and Insulin Sensitivity Recruiting
Neurofeedback-EEG Rehabilitation Protocol on Motor Recovery in the Subacute Phase Post-stroke (CUSTOM-NF-STROKE) Recruiting
Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules Recruiting
Periodontal Microbiota of Patients Candidates for Bariatric Surgery With Body Mass Index Greater Than 30 Recruiting
Effects of an Intensive Rhythmic Dance Program on Learning Skills in Children With Cerebral Palsy Recruiting

Other trials for the same condition

First-in-human Integrated Endoscopic Ultrasound (EUS) Navigation System Clinical Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05824403 on ClinicalTrials.gov ↗ ← All trials in France